Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Diclofenac sodium (GP 45840) 是一种非选择性抗炎剂,是 COX 抑制剂,在 CHO 细胞中,对人 COX-1 和 COX-2 的 IC50值分别为 4 和 1.3 nM。它对绵羊 COX-1 和 COX-2 的 IC50值分别为 5.1 μM,0.84 μM。它通过活化 caspase 级联反应来诱导神经干细胞凋亡。
产品描述 | Diclofenac sodium (GP 45840) is a non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. |
靶点活性 | COX-2:200 nM, COX-1:60 nM |
体外活性 | Diclofenac inhibits Wnt/beta-catenin signaling without altering the level of beta-catenin protein and reduces the expression of beta-catenin/TCF-dependent genes. Diclofenac induces the degradation of IkappaBalpha, which increases free nuclear factor kappaB (NF-kappaB) in colon cancer cells. [1] Diclofenac suppresses both fast tetrodotoxin-sensitive (TTX-S) and the slow tetrodotoxin-resistant (TTX-R) sodium currents in a dose-dependent manner. Diclofenac produces shifts of the steady-state inactivation curves in the hyperpolarizing direction in both types of sodium currents in a dose-dependent manner. Diclofenac may bind to sodium channels with a greater affinity when they are in the inactivated state than when they are in the resting state. [2] Diclofenac results in a severe accumulation of protein in the tubular cells (so called hyaline droplet degeneration), macrophage infiltration and structural alterations (dilation, vesiculation) of the endoplasmic reticulum (ER) in the proximal and distal renal tubules of kidney. Diclofenac also results in shortening of podocytes and their retraction from the basal lamina, a thickening of the basal lamina, the formation of desmosomes, and necrosis of endothelial cells in the renal corpuscles of kidney. [3] |
体内活性 | Diclofenac (0.01 to 0.2 mM) stimulates state-4 respiration and slightly inhibits state 3 in rats, decreasing the respiratory control ratio, while the membrane potential is decreased or collapsed (depending on the drug concentration). [4] |
别名 | GP 45840, 双氯芬酸钠 |
分子量 | 318.13 |
分子式 | C14H10Cl2NNaO2 |
CAS No. | 15307-79-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31.8 mg/mL (100 mM)
H2O: 15.9 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 3.1434 mL | 15.7168 mL | 31.4337 mL | 78.5842 mL |
5 mM | 0.6287 mL | 3.1434 mL | 6.2867 mL | 15.7168 mL | |
10 mM | 0.3143 mL | 1.5717 mL | 3.1434 mL | 7.8584 mL | |
20 mM | 0.1572 mL | 0.7858 mL | 1.5717 mL | 3.9292 mL | |
50 mM | 0.0629 mL | 0.3143 mL | 0.6287 mL | 1.5717 mL | |
DMSO | 100 mM | 0.0314 mL | 0.1572 mL | 0.3143 mL | 0.7858 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Diclofenac sodium 15307-79-6 Apoptosis Immunology/Inflammation Neuroscience COX ovine cascade CHO anti-inflammatory GP 45840 Diclofenac COX-1 Inhibitor NSCs COX-2 inhibit neural 双氯芬酸钠 cells Cyclooxygenase GP-45840 GP45840 caspase stem inhibitor